Filtered By:
Cancer: Lung Cancer
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 49680 results found since Jan 2013.
3 environmental issues disproportionately affecting Hispanic patients
Special factors influencing the health of the Hispanic population stepped into the spotlight during a panel discussion last week. Learn what health care researchers are discovering about environmental factors that impact the health of this underserved patient population.
Researchers and physicians at the event hosted by the AMA Minority Affairs Section and the National Hispanic Medical Association discussed how multiple factors—ranging from a lack of Hispanic physicians in medicine to lurking environmental contaminants—shape Hispanic health. Some of the top issues they discussed included:
The impact of environ...
Source: AMA Wire - October 13, 2015 Category: Journals (General) Authors: amamod Source Type: news
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and develop disease progression. Conventional practice would be to switch treatments to second-line therapy. However, continuing TKIs beyond progression is becoming increasingly commonplace in patients with indolent, small volume asymptomatic growth, who may potentially continue to derive ongoing clinical benefit and to avoid a ‘withdrawal tumour flare’.
Source: European Journal of Cancer - November 16, 2016 Category: Cancer & Oncology Authors: Timothy A. Yap, Aislinn Macklin-Doherty, Sanjay Popat Tags: Review Source Type: research
Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
Conclusion: Continuation of crizotinib therapy after RECIST-PD in Chinese NSCLC patients with positive ALK/ROS1 mutations is feasible in clinical practice.
Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Jun Liu, Shaohua Cui, Feng Pan, Yiqian Ni, Hua Zhong, Liwen Xiong, Bo Jin, Tianqing Chu, Aiqin Gu, Liyan Jiang Tags: Research Paper Source Type: research
Cancer Mortality Continuing to Drop, With Lung Cancer a Driver
WEDNESDAY, Jan. 8, 2020 -- Cancer mortality is continuing to decline, driven by progress in lung cancer, although mortality reductions have slowed or stopped for some cancers, according to findings included in Cancer Statistics, 2020, the American...
Source: Drugs.com - Pharma News - January 8, 2020 Category: Pharmaceuticals Source Type: news
Commentary: Do we need to search for a patient's cigarettes or just count his or her wrinkles when counseling for lung cancer resection?
Smoking increases your risk of problems during and after your operation. Quit smoking 4-6 weeks before your operation. That is a morsel of strong advice among many provided in the surgical patient education program published by the American College of Surgeons to prepare for the best recovery after surgery.1
Source: The Journal of Thoracic and Cardiovascular Surgery - December 24, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Dirk Van Raemdonck, Herbert Decaluwe, Paul De Leyn, Kristiaan Nackaerts Tags: Commentary Source Type: research
Association between Albumin, Total Bilirubin, and Uric Acid Serum Levels and the Risk of Cancer: A Prospective Study in a Korean Population
CONCLUSION: The findings of this study support the role of antioxidants in carcinogenesis. Future large-cohort studies are needed to confirm the predictive value of albumin, UA, and total bilirubin levels in each type of cancer.PMID:34427064 | PMC:PMC8382725 | DOI:10.3349/ymj.2021.62.9.792
Source: Yonsei Medical Journal - August 24, 2021 Category: Universities & Medical Training Authors: Ye Rim Kim Chang Kyun Choi Young Hoon Lee Seong Woo Choi Hye Yeon Kim Min Ho Shin Sun Seog Kweon Source Type: research
